Alnylam Pharmaceuticals
ALNY
ALNY
292 hedge funds and large institutions have $10.9B invested in Alnylam Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 114 increasing their positions, 83 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
2.24% less ownership
Funds ownership: 93.75% → 91.51% (-2.2%)
7% less capital invested
Capital invested by funds: $11.7B → $10.9B (-$792M)
14% less funds holding in top 10
Funds holding in top 10: 14 → 12 (-2)
Holders
292
Holding in Top 10
12
Calls
$109M
Puts
$105M
Top Buyers
| 1 | +$97.6M | |
| 2 | +$50.1M | |
| 3 | +$44.1M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$40M |
| 5 |
O
OrbiMed
New York
|
+$38.6M |
Top Sellers
| 1 | -$421M | |
| 2 | -$32.5M | |
| 3 | -$27.2M | |
| 4 |
Goldman Sachs
New York
|
-$21.1M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$15.5M |